Idorsia Ltd is a Swiss biopharmaceutical company headquartered in Allschwil, Switzerland, near Basel, focused on discovering and developing innovative drugs for rare diseases and central nervous system disorders. The company was founded in 2017 as a spin-off from Actelion, following Johnson & Johnson's acquisition of Actelion.
Idorsia was established with a portfolio of promising clinical and preclinical compounds from Actelion's pipeline, along with a team of experienced drug hunters. The company operates with a dual focus on rare diseases and CNS disorders, leveraging its expertise in GPCR pharmacology and drug discovery[1].
Idorsia was created in 2017 when Johnson & Johnson acquired Actelion for $30 billion. As part of the deal, Actelion's pipeline assets and research team were spun out to form Idorsia, with Jean-Paul and Martine Clozel (former Actelion leadership) leading the new company.
| Drug | Indication | Mechanism | Approval |
|---|---|---|---|
| QUVIVIQ (Daridorexant) | Insomnia | Orexin-2 receptor antagonist | FDA 2022[2] |
| Drug Candidate | Target | Indication | Stage |
|---|---|---|---|
| Daridorexant | Orexin-2 | Insomnia | Approved |
| Clazosentan | Endothelin-A | Aneurysmal subarachnoid hemorrhage | Phase 3[3] |
| Lucerastat | Glucosylceramide synthase | Fabry disease | Phase 3 |
| Aplindore | Dopamine D2 | Parkinson's disease | Phase 2 |
| ACT-709478 | Unknown | Epilepsy | Phase 1 |
Daridorexant represents a novel mechanism for insomnia treatment. Unlike traditional hypnotics that target GABA receptors, daridorexant blocks orexin neuropeptides that promote wakefulness[4]:
Lucerastat is a substrate reduction therapy for Fabry disease:
Clazosentan is an endothelin-A receptor antagonist being developed to prevent cerebral vasospasm following aneurysmal subarachnoid hemorrhage:
Idorsia's platform is built on deep expertise in G protein-coupled receptor (GPCR) pharmacology. This class of receptors includes many druggable targets for CNS and metabolic disorders:
The company maintains a discovery engine capable of:
Idorsia's CNS pipeline has significant implications for neurodegenerative and neurological disorders[6]:
Sleep Disorders: Daridorexant represents a paradigm shift in insomnia treatment with a novel mechanism that avoids dependence and withdrawal issues associated with benzodiazepines.
Parkinson's Disease: Aplindore targets dopamine D2 receptors with a different pharmacological profile than current dopamine agonists, potentially offering benefits with reduced side effects.
Epilepsy: ACT-709478 represents a novel anticonvulsant mechanism.
Neuroprotection: The company's GPCR expertise positions it to develop neuroprotective agents.
Idorsia has established partnerships to support its development programs:
Idorsia Pipeline. Corporate Presentation. ↩︎
Daridorexant Approval. FDA Press Release. ↩︎
Clazosentan Development. ClinicalTrials.gov. ↩︎
Daridorexant Mechanism. Journal of Pharmacology and Experimental Therapeutics. ↩︎
Lucerastat in Fabry Disease. Journal of Inherited Metabolic Disease. ↩︎
Idorsia CNS Programs. Investor Presentation. ↩︎